Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1119
Abstract: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of hyperuricemia and gout. This phase 1b, multiple‐dose, drug‐drug interaction study evaluated the pharmacokinetics, pharmacodynamics, and tolerability of verinurad in combination… read more here.
Keywords: verinurad allopurinol; verinurad; multiple dose; pharmacodynamics tolerability ... See more keywords
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-00706-7
Abstract: Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1. Here, we characterize verinurad (RDEA3170), which is currently under evaluation for gout therapy. Verinurad specifically… read more here.
Keywords: uric acid; urat1 inhibitors; verinurad; characterization verinurad ... See more keywords
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
Sign Up to like & getrecommendations! Published in 2018 at "RMD Open"
DOI: 10.1136/rmdopen-2017-000584
Abstract: Objectives Verinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1) inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad combined with allopurinol… read more here.
Keywords: verinurad; adults gout; safety verinurad; phase iia ... See more keywords